Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized autologous ATA190 study in progressive MS patients

Trial Profile

A randomized autologous ATA190 study in progressive MS patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATA-190 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2019 According to an Atara Biotherapeutics media release, the company will not initiate a randomized study of autologous ATA190 in progressive MS at this time and will evaluate strategic options for this program. The company's decision is based on continued encouraging ATA188 results, acceleration of the ATA188 randomized Phase 1b study and the Company's strategic focus on off-the-shelf, allogeneic T-cell immunotherapies.
    • 09 May 2019 According to an Atara Biotherapeutics media release, the company expected to initiate this study in the second half of 2019.
    • 08 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top